127 related articles for article (PubMed ID: 34929228)
1. The immune microenvironment of the hydatidiform mole.
Dridi M; Papoudou-Bai A; Kanavaros P; Perard M; Clemenson A; Chauleur C; Peoc'h M; Karpathiou G
Hum Pathol; 2022 Feb; 120():35-45. PubMed ID: 34929228
[TBL] [Abstract][Full Text] [Related]
2. Decidual infiltration of FoxP3⁺ regulatory T cells, CD3⁺ T cells, CD56⁺ decidual natural killer cells and Ki-67 trophoblast cells in hydatidiform mole compared to normal and ectopic pregnancies.
Sundara YT; Jordanova ES; Hernowo BS; Gandamihardja S; Fleuren GJ
Mol Med Rep; 2012 Jan; 5(1):275-81. PubMed ID: 22002546
[TBL] [Abstract][Full Text] [Related]
3. Decidual immune cell infiltrate in hydatidiform mole.
Hussein MR; Abd-Elwahed AR; Abodeif ES; Abdulwahed SR
Cancer Invest; 2009 Jan; 27(1):60-6. PubMed ID: 19160109
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of leukemia inhibitory factor and insulin like growth factor-1 between normal pregnancies, partial hydatidiform moles and complete hydatidiform moles.
Yucel Cicek OS; Hekimoglu ER; Turgal M; Atilla P; Cakar AN; Usubutun A; Beksac MS
Placenta; 2018 Sep; 69():64-70. PubMed ID: 30213486
[TBL] [Abstract][Full Text] [Related]
5. PHENOTYPIC CHARACTERISTICS OF TROPHOBLASTIC HYPERPLASIA AND MICROENVIRONMENT ALTERATIONS IN CHORIONIC VILLI IN SPONTANEOUS ABORTIONS.
Chikvaidze N; Kintraia N; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 Jun; (291):117-121. PubMed ID: 31418743
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Zhang SS; Wan XY; Zhou CY; Lü WG; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2011 Jul; 46(7):510-5. PubMed ID: 22041443
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic index for prediction of postmolar gestational trophoblastic neoplasia.
Braga A; Maestá I; Rocha Soares R; Elias KM; Custódio Domingues MA; Barbisan LF; Berkowitz RS
Am J Obstet Gynecol; 2016 Sep; 215(3):336.e1-336.e12. PubMed ID: 27094961
[TBL] [Abstract][Full Text] [Related]
8. Pathology of gestational trophoblastic diseases.
Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2003 Dec; 17(6):849-68. PubMed ID: 14614885
[TBL] [Abstract][Full Text] [Related]
9. Centralized surveillance of hydatidiform mole: 7-year experience from a regional hospital in China.
Jiao L; Wang Y; Jiang J; Wang X; Zhang W; Zhu C; Xiang Y
Int J Gynecol Cancer; 2022 Feb; 32(2):147-152. PubMed ID: 34799419
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and significance of implantation site trophoblastic atypia in hydatidiform moles and spontaneous abortions.
Montes M; Roberts D; Berkowitz RS; Genest DR
Am J Clin Pathol; 1996 Apr; 105(4):411-6. PubMed ID: 8604683
[TBL] [Abstract][Full Text] [Related]
11. Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease.
Petts G; Fisher RA; Short D; Lindsay I; Seckl MJ; Sebire NJ
J Reprod Med; 2014; 59(5-6):213-20. PubMed ID: 24937960
[TBL] [Abstract][Full Text] [Related]
12. Partial hydatidiform mole: a common but underdiagnosed condition. A 3-year retrospective clinicopathological and DNA flow cytometric analysis.
Jeffers MD; O'Dwyer P; Curran B; Leader M; Gillan JE
Int J Gynecol Pathol; 1993 Oct; 12(4):315-23. PubMed ID: 8253548
[TBL] [Abstract][Full Text] [Related]
13. Decidual T lymphocyte activation in hydatidiform mole.
Wongweragiat S; Searle RF; Bulmer JN
J Clin Pathol; 1999 Dec; 52(12):888-94. PubMed ID: 10711251
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fas/Fas ligand by decidual leukocytes in hydatidiform mole.
Wongweragiat S; Searle RF; Bulmer JN
Biol Reprod; 2001 Mar; 64(3):784-9. PubMed ID: 11207192
[TBL] [Abstract][Full Text] [Related]
15. P63 expression in hydropic abortion and gestational trophoblastic diseases.
Ramalho LN; Maggiori MS; Ribeiro-Silva A; Peres LC
Placenta; 2006; 27(6-7):740-3. PubMed ID: 16026831
[TBL] [Abstract][Full Text] [Related]
16. Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease.
Lewis GH; DeScipio C; Murphy KM; Haley L; Beierl K; Mosier S; Tandy S; Cohen DS; Lytwyn A; Elit L; Vang R; Ronnett BM
Int J Gynecol Pathol; 2013 Mar; 32(2):199-214. PubMed ID: 23370656
[TBL] [Abstract][Full Text] [Related]
17. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression.
Lin LH; Maestá I; St Laurent JD; Hasselblatt KT; Horowitz NS; Goldstein DP; Quade BJ; Sun SY; Braga A; Fisher RA; Berkowitz RS; Elias KM
Am J Obstet Gynecol; 2021 Apr; 224(4):372.e1-372.e30. PubMed ID: 33031755
[TBL] [Abstract][Full Text] [Related]
18. Quantitative morphology. A study of the trophoblast.
Franke HR; Alons CL; Caron FJ; Boog MC; Oort J; Stolk JG
Virchows Arch A Pathol Anat Histopathol; 1985; 406(3):323-31. PubMed ID: 3923708
[TBL] [Abstract][Full Text] [Related]
19. An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy.
Stone M; Bagshawe KD
Br J Obstet Gynaecol; 1979 Oct; 86(10):782-92. PubMed ID: 228696
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferative activity and mutation of P53 suppressor gene in human gestational trophoblastic disease.
Persaud V; Ganjei P; Nadji M
West Indian Med J; 1993 Dec; 42(4):142-3. PubMed ID: 7909185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
